Overview of Sigma Healthcare’s Recent Performance
Sigma Healthcare Ltd, listed on the Australian Securities Exchange (ASX) under the ticker symbol SIG, has experienced a fluctuating share price in recent months. As of Friday, the stock was trading at $2.73, reflecting a 0.9% increase for the day but a 7.3% decline year-to-date. This performance comes after the company merged with Chemist Warehouse last year, expanding its portfolio to include other pharmacy chains such as Amcal and Discount Drug Stores.
The merger, which was completed in February 2025, initially boosted the share price significantly, reaching a multi-decade high of $3.28 by June. The combined entity now operates over 880 franchised pharmacies and supplies more than 3,500 chemists across Australia. Additionally, the company has operations in New Zealand, Ireland, and the United Arab Emirates.
However, market enthusiasm around the deal began to wane in the second half of last year. Since its peak, the share price has dropped by 17%, with the stock touching a 15-month low of $2.58 in the previous month. This decline has been accompanied by broader challenges within the healthcare sector.
Morgans’ Upgrade and Outlook
In response to the ongoing share price weakness, Morgans has upgraded its rating on Sigma Healthcare from “accumulate” to “buy.” In a recent note titled “Prescribing Long-Term Growth,” the broker maintained its 12-month share price target at $3.36. Morgans anticipates about 20% growth in earnings before interest and taxes (EBIT) over the next few years, driven by strong like-for-like sales growth and the expansion of new stores both domestically and internationally.
The broker also expects operational efficiencies and approximately $100 million per annum in synergies by FY29. Morgans noted that the share price weakness prompted the upgrade, offering a 26% upside potential from the current level. The firm previously described Sigma Healthcare’s 1H FY26 report as “solid” and in line with consensus expectations.
Other Analysts’ Perspectives
Other analysts have also revised their views on Sigma Healthcare in recent weeks. Ord Minnett and Jefferies have upgraded the shares to a “buy” rating, though Ord Minnett lowered its 12-month target from $3.40 to $3.30, while Jefferies maintains a target of $3.05.
RBC Capital recently initiated coverage on the ASX healthcare share with a “hold” rating and a $2.50 target. Macquarie also has a “hold” rating and increased its share price target from $3 to $3.20 early last month. Jarden upgraded Sigma Healthcare shares to a “buy” rating in late February, setting a $3.60 price target.
Investment Considerations
Before investing in Sigma Healthcare, it is essential to consider various factors. Motley Fool investing expert Scott Phillips recently highlighted what he believes are the five best stocks for investors to buy at this time, although Sigma Healthcare was not among them. The online investing service Motley Fool Share Advisor has provided thousands of paying members with stock picks that have delivered significant returns.
For those considering an investment in Sigma Healthcare, it is important to assess the company’s long-term prospects, market conditions, and overall financial health. While the recent upgrades from some analysts suggest optimism, the share price remains volatile, and the broader healthcare sector continues to face challenges.
Additional Reading
There are several other articles and analyses available that provide insights into the performance of ASX healthcare shares. For instance, some ASX 200 shares, including WiseTech and Xero, have reached 52-week-plus lows. Additionally, there are discussions on whether certain ASX 200 stocks present attractive buying opportunities following their declines.
Investors should also be aware of the potential risks associated with investing in the healthcare sector, as heavyweights in the industry have hit multi-year lows. Despite these challenges, some analysts continue to highlight specific ASX shares that may offer long-term growth potential.
